Streetwise Management Q&As


J. Joseph Kim

Inovio Moves Forward on Brain Cancer and Cancers Caused by HPV; Zika and Ebola Vaccines Also Advance
Source: The Life Sciences Report  (5/17/17)
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. More >


Kevin Little

3D Signatures' Platform Taps into the Power of the Genome
Source: The Life Sciences Report  (5/10/17)
How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment. More >


Elliot Goldstein

The ProMIS of an Alzheimer's Cure
Source: The Life Sciences Report  (5/3/17)
With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report.
More >


Stephen de Jong

Integra Gold Is Entering Unicorn Territory
Source: The Gold Report  (4/6/17)
Companies tend to excel at exploration or development, but Integra Gold seems to do both well simultaneously. In this interview with The Gold Report, Integra CEO Stephen de Jong explains Integra's dual track, discusses the company's latest PEA and resource update, and enumerates Integra's path to production. More >


James Brown

Many Paths to Success with DURECT's Pipeline
Source: Dr. James Brown for The Life Sciences Report  (3/29/17)
DURECT has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the potentially groundbreaking epigenetic regulator DUR-928, POSIMIR's late-stage testing for postoperative pain and an abuse-deterrent oral technology. More >


Ross McElroy

Fission Uranium's Exploratory Drilling Hits Success Right Out of the Gate
Source: Ross McElroy for The Energy Report  (3/23/17)
With uranium up 40% off last year's lows, a glimmer of optimism is returning to the uranium market, says Fission Uranium's President, COO and Chief Geologist Ross McElroy. In this interview with The Energy Report, McElroy discusses the company's latest drill results, its winter drilling plans and why he believes Fission could be on the cusp of a major discovery. More >


Great Panther Is on the Prowl for Acquisitions
Source: Bob Archer for The Gold Report  (3/14/17)
Great Panther Silver's modus operandi is to buy a past-producing mine, get it up and running as quickly as possible, and use the cash flow to fund more acquisitions, says CEO Bob Archer in this interview with The Gold Report. Having succeeded in Mexico with Guanajuato and Topia, the company is now taking on Coricancha in Peru. More >


MAG Silver's World-Class Property Just Keeps Getting Better
Source: The Gold Report  (3/7/17)
MAG Silver appears to have the Midas touch: Everything it drills turns up silver—with a gold byproduct and lots of zinc, lead and copper thrown in for good measure. MAG's first drill hole discovered the Juanicipio vein and hole #16 discovered the Valdecañas vein, both world-class deposits. In this interview with The Gold Report, MAG CEO George Paspalas discusses the company's JV in the Fresnillo Trend, the latest off-the-chart deep discoveries and where MAG goes from here. More >


RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
Source: The Life Sciences Report  (2/22/17)
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. More >


Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Source: The Life Sciences Report  (8/17/16)
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. More >


Rudi Fronk

Seabridge Is Turning Cash into Gold
Source: The Gold Report  (8/4/16)
Seabridge Gold hosts one of the world's largest gold resources, offering shareholders exceptional leverage to a rising gold price. Chairman and CEO Rudi Fronk explains his company's value-enhancing strategy of obtaining resources at low cost and spinning them into gold. More >


Mark Kolebaba

Potential of High-Grade Gold Deposits Draws Adamera to Washington
Source: The Gold Report  (6/23/16)
Washington State has seen substantial historical gold mining dating back to the 1890s, but that doesn't mean there still isn't gold to be mined. Mark Kolebaba, CEO of Adamera Minerals, extols the advantages of exploring in Washington and explains why it offers low-cost opportunities. More >


Quaterra's Agreement with Freeport Nevada Extends Yerington Funding
Source: Special to The Gold Report  (6/14/16)
Quaterra Resources Inc. and its subsidiary Singatse Peak Services announced earlier this week that they had reached an agreement with Freeport Nevada to extend for up to two years the current Stage 2 of Freeport Nevada's option to acquire an interest in the company's Yerington Copper Project in Nevada. Gerald Prosalendis, recently appointed president and COO of Quaterra Resources, explains what this extension means for Quaterra and the Yerington project. More >


Punit Dhillon

OncoSec Delivers Cancer Therapy Straight to the Tumor
Source: Special to The Life Sciences Report  (6/1/16)
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment. More >


Kolin Ozonian

How Nobilis Health Will Break Out of the Healthcare Payment Mold
Source: George S. Mack of The Life Sciences Report   (5/25/16)
Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise. In this interview with The Life Sciences Report, Ozonian discusses his company's newest technology and talks about how Nobilis will achieve critical mass. More >


Domenic Della Penna

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
Source: Special to The Life Sciences Report  (5/11/16)
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications. More >


James Joyce

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
Source: Special to The Life Sciences Report  (5/4/16)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. More >


Christopher Schaber

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
Source: Special to The Life Sciences Report  (4/27/16)
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases—a type of lymphoma and pediatric Crohn's disease—are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio. More >


Michael Becker

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse
Source: Special to The Life Sciences Report  (4/20/16)
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
More >


Frank Oakes

Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans
Source: Staff of The Life Sciences Report  (4/5/16)
Frank Oakes, the chairman, president and CEO of Stellar Biotechnologies, has a passion for the potential life-saving cures the ocean may provide. His company, a world leader in the production of sustainable, scalable and fully traceable GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH, and Oakes himself has more than three decades of management experience in aquaculture. In this interview with The Life Sciences Report, Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. More >


David Kalergis

Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis
Source: George S. Mack of The Life Sciences Report  (3/30/16)
It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma. That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. finds itself, says CEO David Kalergis. In this interview with The Life Sciences Report, Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful. More >


Lisa Crossley

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Source: Special to The Life Sciences Report  (3/29/16)
Because chronic conditions are difficult to manage by patients at home, with complications, hospitalizations and other expensive interventions sometimes necessary, they account for more than 75% of healthcare costs worldwide. To meet this need, Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview with The Life Sciences Report, Moseda's CEO, Dr. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care. More >


Douglas Forster

Newmarket Gold's Shares Up 75% in 2016 and That Is Just the Beginning
Source: Paul Guedes of The Gold Report  (3/29/16)
Newmarket Gold's shares have appreciated 75% since the beginning of 2016, but CEO Douglas Forster believes that is just the beginning. The company's storied founders have set their sights on making Newmarket the next high-quality mid-tier gold producer. In this interview with The Gold Report, Forster puts forth his vision of how, starting with the acquisition of Crocodile Gold, he will make that happen. More >


Kolin Ozonian

Nobilis Health Doubles Down, Offering Organic Growth and Aggressive Acquisitions: Kolin Ozonian
Source: George S. Mack of The Life Sciences Report  (3/23/16)
Businesses can grow in two ways—internally and externally. Nobilis Health Corp. has a voracious appetite for both. The company is a development and management firm that acquires private outpatient surgical centers—in short, it's a business model built on efficiencies. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches. In this interview with The Life Sciences Report, Nobilis' mergers-and-acquisitions specialist Kolin Ozonian talks about the business model and tells investors how he and the Nobilis team plan to aggressively grow the company. More >


Gary Economo

Graphite: What iPhones, NASCAR and Tesla Have in Common
Source: Special to The Gold Report  (2/29/16)
Focus Graphite CEO and Director Gary Economo says the tipping point is coming for natural flake mining developers—even during a depressed commodities cycle. This optimistic view is based on the urgent necessity of manufacturers today to source those critical materials and technologies needed to meet globally mandated CleanTech targets in advance of a 2020 deadline. Focus, says Economo, is on strategic trajectory to capitalize on global change with his company's high-purity graphite deposit, Lac Knife in Quebec. More >


Showing Results: 1 to 25 of 97 Next

More Experts